Matching articles for "age-related macular degeneration"
Issue 1720 · January 20, 2025
Valeda Light Delivery System for Age-Related Macular Degeneration

The FDA has authorized use of the Valeda Light Delivery System (LumiThera), a multiwavelength photobiomodulation (PBM) device, to improve visual acuity in patients with dry age-related macular degeneration…

Med Lett Drugs Ther. 2025 Jan 20; 67(1720):9-10 doi:10.58347/tml.2025.1720a
The FDA has authorized use of the Valeda Light Delivery System (LumiThera), a multiwavelength photobiomodulation (PBM) device, to improve visual acuity in patients with dry age-related macular degeneration (AMD) who have best-corrected visual acuity (BCVA) of 20/32 to 20/70.
Issue 1719 · January 6, 2025
Drugs for Age-Related Macular Degeneration

Age-related macular degeneration (AMD) has two major forms: dry or non-neovascular (~90% of patients) and wet or neovascular (~10% of patients).

Med Lett Drugs Ther. 2025 Jan 6; 67(1719):1-5 doi:10.58347/tml.2025.1719a
Age-related macular degeneration (AMD) has two major forms: dry or non-neovascular (~90% of patients) and wet or neovascular (~10% of patients).
Issue 1694 · January 22, 2024
Avacincaptad Pegol (Izervay) for Geographic Atrophy in Age-Related Macular Degeneration

The FDA has approved the complement C5 inhibitor avacincaptad pegol ( Izervay – Iveric) for intravitreal treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Avacincaptad…

Med Lett Drugs Ther. 2024 Jan 22; 66(1694):15-6 doi:10.58347/tml.2024.1694d
The FDA has approved the complement C5 inhibitor avacincaptad pegol ( Izervay – Iveric) for intravitreal treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Avacincaptad pegol is the second complement inhibitor to be approved in the US for this indication; pegcetacoplan (Syfovre) , a complement C3 and C3b inhibitor, was approved earlier.
Issue 1673 · April 3, 2023
Pegcetacoplan (Syfovre) for Geographic Atrophy in Age-Related Macular Degeneration

The FDA has approved the complement C3 inhibitor pegcetacoplan ( Syfovre – Apellis) for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Given as a series of monthly…

Med Lett Drugs Ther. 2023 Apr 3; 65(1673):49-50 doi:10.58347/tml.2023.1673a
The FDA has approved the complement C3 inhibitor pegcetacoplan ( Syfovre – Apellis) for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Given as a series of monthly or every-other-month (EOM) intravitreal injections, it is the first drug to become available for use in patients with atrophic dry AMD. Subcutaneous pegcetacoplan was approved earlier as Empaveli for treatment of paroxysmal nocturnal hemoglobinuria.
Issue 1649 · May 2, 2022
A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular Degeneration

The FDA has approved Susvimo (Genentech), a refillable permanent ocular implant containing the vascular endothelial growth factor (VEGF) inhibitor ranibizumab, for treatment of neovascular (wet) age-related…

Med Lett Drugs Ther. 2022 May 2; 64(1649):71-2
The FDA has approved Susvimo (Genentech), a refillable permanent ocular implant containing the vascular endothelial growth factor (VEGF) inhibitor ranibizumab, for treatment of neovascular (wet) age-related macular degeneration (nAMD) in patients who have previously responded to at least two intravitreal injections of a VEGF inhibitor. Ranibizumab intravitreal injection (Lucentis) has been available since 2006 for monthly treatment of nAMD. The FDA has approved ranibizumab-nuna (Byooviz) , a biosimilar of Lucentis and the first ophthalmologic biosimilar; it will be available in June 2022.
Issue 1646 · March 21, 2022
Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema

Faricimab-svoa ( Vabysmo – Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of neovascular (wet)…

Med Lett Drugs Ther. 2022 Mar 21; 64(1646):45-6
Faricimab-svoa ( Vabysmo – Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). It is the first drug to become available in the US that targets two pathways involved in maintaining vascular homeostasis. Several VEGF inhibitors are available for treatment of nAMD and DME (see Table 2).
Issue 1593 · March 9, 2020 Free
Addendum: Brolucizumab (Beovu) for Age-Related Macular Degeneration

We reviewed brolucizumab ( Beovu – Novartis) for treatment of neovascular (wet) age-related macular degeneration in our February 10 issue. On February 23, the American Society of Retina Specialists reported…

Med Lett Drugs Ther. 2020 Mar 9; 62(1593):40
We reviewed brolucizumab ( Beovu – Novartis) for treatment of neovascular (wet) age-related macular degeneration in our February 10 issue. On February 23, the American Society of Retina Specialists reported that 14 patients who received the drug have developed retinal vasculitis, a potentially vision-threatening complication.
Issue 1591 · February 10, 2020
Brolucizumab (Beovu) for Age-Related Macular Degeneration

Brolucizumab-dbll ( Beovu — Novartis), a vascular endothelial growth factor (VEGF) inhibitor, has been approved by the FDA as an intravitreal injection for treatment of neovascular (wet) age-related macular…

Med Lett Drugs Ther. 2020 Feb 10; 62(1591):23-4
Brolucizumab-dbll ( Beovu — Novartis), a vascular endothelial growth factor (VEGF) inhibitor, has been approved by the FDA as an intravitreal injection for treatment of neovascular (wet) age-related macular degeneration (AMD). It is the fourth VEGF inhibitor to be approved in the US for this indication; bevacizumab ( Avastin , and others), a VEGF inhibitor FDA-approved for treatment of breast cancer and other malignancies, has been used off-label for this indication for years.
Issue 1586 · December 2, 2019
Drugs for Common Eye Disorders

This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate issue.

Med Lett Drugs Ther. 2019 Dec 2; 61(1586):187-94
This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate issue.
Issue 1464 · March 16, 2015
VEGF Inhibitors for AMD and Diabetic Macular Edema

Vascular endothelial growth factor (VEGF) is a principal mediator of neovascularization in wet age-related macular degeneration (AMD) and diabetic macular edema. It induces angiogenesis and increases vascular…

Med Lett Drugs Ther. 2015 Mar 16; 57(1464):41-2
Vascular endothelial growth factor (VEGF) is a principal mediator of neovascularization in wet age-related macular degeneration (AMD) and diabetic macular edema. It induces angiogenesis and increases vascular permeability and inflammation. VEGF inhibitors reduce leakage from blood vessels, prevent proliferation of new abnormal vessels, decrease swelling of the retina, and improve visual acuity in patients with neovascular (wet) AMD and diabetic macular edema. These drugs are given as periodic intravitreal injections with topical anesthesia.
Issue 1419 · June 24, 2013
Nutritional Supplements for Age-Related Macular Degeneration Revisited

The results of the Age-Related Eye Disease Study 2 (AREDS2) have now been published. The primary purpose of the study was to evaluate the efficacy and safety of the carotenoids lutein and zeaxanthin and the…

Med Lett Drugs Ther. 2013 Jun 24; 55(1419):50-1
The results of the Age-Related Eye Disease Study 2 (AREDS2) have now been published. The primary purpose of the study was to evaluate the efficacy and safety of the carotenoids lutein and zeaxanthin and the omega-3 polyunsaturated fatty acids (PUFAs) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in reducing the risk of developing advanced age-related macular degeneration (AMD). A secondary goal was to test the effects of reducing the amount of zinc and eliminating beta carotene from the original AREDS formulation. Beta carotene has been shown to increase the risk of lung cancer in smokers and former smokers.
Issue 123 · November 1, 2012
Drugs for Some Common Eye Disorders

Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Drugs for the treatment of allergic conjunctivitis will be reviewed in a future issue of…

Treat Guidel Med Lett. 2012 Nov; 10(123):79-86
Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Drugs for the treatment of allergic conjunctivitis will be reviewed in a future issue of Treatment Guidelines on Drugs for Allergic Disorders.
Issue 1383 · February 6, 2012
Aflibercept (Eylea) for Age-Related Macular Degeneration

The FDA has approved aflibercept (a flib’ er sept; Eylea – Regeneron) for treatment of neovascular (wet) age-related macular degeneration (AMD).

Med Lett Drugs Ther. 2012 Feb 6; 54(1383):9-10
The FDA has approved aflibercept (a flib’ er sept; Eylea – Regeneron) for treatment of neovascular (wet) age-related macular degeneration (AMD).
Issue 1344 · August 9, 2010
Nutritional Support for Macular Degeneration

An advertisement in a recent issue of Ophthalmology introduces PreserVision Eye Vitamin AREDS 2 Formula from Bausch & Lomb. No specific indication is mentioned, but the ad states that “…[the new product]…

Med Lett Drugs Ther. 2010 Aug 9; 52(1344):63
An advertisement in a recent issue of Ophthalmology introduces PreserVision Eye Vitamin AREDS 2 Formula from Bausch & Lomb. No specific indication is mentioned, but the ad states that “…[the new product] builds on the original PreserVision Eye Vitamin AREDS Formula , the only formula proven to slow the progression of moderate-to-advanced AMD.”
Issue 89 · January 1, 2010
Drugs for Some Common Eye Disorders

Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly…

Treat Guidel Med Lett. 2010 Jan; 8(89):1-8
Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly patients, the complexity of self-administering numerous ophthalmic drugs may be the limiting factor in their ability to care for themselves. Drugs for the treatment of allergic conjunctivitis will be reviewed in a future issue of Treatment Guidelines on Drugs for Allergic Disorders.
Issue 53 · January 1, 2007
Drugs for Some Common Eye Disorders

Drugs for glaucoma, age-related macular degeneration, bacterial and allergic conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some…

Treat Guidel Med Lett. 2007 Jan; 5(53):1-8
Drugs for glaucoma, age-related macular degeneration, bacterial and allergic conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly patients, the complexity of self-administering numerous ophthalmic drugs may be the limiting factor in their ability to care for themselves.
Issue 1246 · October 23, 2006
Ranibizumab (Lucentis) for Macular Degeneration

The FDA has approved ranibizumab ( Lucentis - Genentech) as an intravitreal injection for treatment of neovascular (wet) age-related macular degeneration (AMD). Ranibizumab is a derivative of bevacizumab…

Med Lett Drugs Ther. 2006 Oct 23; 48(1246):85-6
The FDA has approved ranibizumab ( Lucentis - Genentech) as an intravitreal injection for treatment of neovascular (wet) age-related macular degeneration (AMD). Ranibizumab is a derivative of bevacizumab (Avastin) , which is FDA-approved for intravenous treatment of metastatic colorectal cancer and nonsmall cell lung cancer, but has also been used off label for intravitreal treatment of neovascular AMD.
Issue 1158 · June 8, 2003
Antioxidant Vitamins and Zinc for Macular Degeneration

High doses of beta carotene, vitamin C, vitamin E and zinc oxide are now being promoted to the general public to "preserve eye health" (Ocuvite PreserVision) , "promote retinal and visual health" (VisiVite)…

Med Lett Drugs Ther. 2003 Jun 8; 45(1158):45-6
High doses of beta carotene, vitamin C, vitamin E and zinc oxide are now being promoted to the general public to "preserve eye health" (Ocuvite PreserVision) , "promote retinal and visual health" (VisiVite) and "preserve healthy vision" (ICaps) . Internet advertisements for these products all refer to a clinical trial, the Age-Related Eye Disease Study (AREDS), which was conducted in patients with age-related macular degeneration (AMD).